Tests SA53-OS, a new oral drug, in adults with advanced solid tumors
Tests SA53-OS, an oral drug, in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
Key facts
- Where
- Canton and Cleveland, United StatesSee the 3 sites
- Phase
- Phase 1/2
Where in United States
- Gabrail Cancer CenterCanton, United StatesTaking people
- Cleveland Clinic Taussig Cancer InstituteCleveland, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lamassu Bio Inc
- Trial code
- NCT06578624
- Record updated
- 9 November 2026
- Original description
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors.Read full original descriptionShow less
A Phase 1/2a, Open-Label Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SA53-OS, an MDM2 Inhibitor, in Patients With Locally Advanced or Metastatic p53 Wild-Type Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors.
The study is comprised of 2 parts: Part 1 called dose escalation, and Part 2a called dose expansion. This study starts with Part 1 where participants who are diagnosed with advanced or metastatic solid tumor cancers receive different doses of SA53-OS (starting with the lowest dose) to find the maximum tolerated dose (MTD) of SA53-OS. Once the MTD of SA53-OS is known, the study continues to Part 2a where participants who are diagnosed with dedifferentiated liposarcoma (DD LPS) or other solid tumor cancers will receive SA53-OS at the MTD.
The study drug, SA53-OS, will be administered for 3 consecutive days every 3 weeks as an oral solution for up to 2 years.
Inclusion: Tumor characteristics of participants in Phase 1; Histologically and/or cytologically confirmed diagnosis of advanced or metastatic solid tumor and/or non-Hodgkin lymphoma excluding primary central nervous system malignancy for which no standard effective treatment exists or where that treatment was declined. Participants with non-Hodgkin lymphoma should have failed ≥ 2 prior lines of systemic therapy prior enrollment; Tumor p53 wild-type; Tumor characteristics of participants in Phase 2a; Cohort A: Tumor p53 wild-type with histologically confirmed diagnosis of advanced or metastatic DD LPS (and MDM2 amplification); OR Cohort B: Tumor p53 wild-type in other solid tumor; Measurable disease by RECIST 1.1; 18 years old or older; Resolution of clinically relevant toxicity-related to prior anticancer therapies prior to receipt of study treatment to Grade 1 or less; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Participants of childbearing/reproductive potential must agree to use adequate birth control measures during the course of the trial and for at least 3 months after discontinuing study treatment.
Exclusion: Anticipated need for major surgery and/or localized palliative radiation within the next 6 weeks; Active, untreated central nervous system metastases. Participants with brain metastases identified at Screening may be rescreened after the lesion(s) have been appropriately treated; participants with treated brain metastases should be neurologically stable for 4 weeks post-treatment and prior to study enrollment, and off corticosteroids for at least 2 weeks before start of study treatment, and treated lesions should demonstrate no new growth on the re-screening scan; Thrombotic event requiring active and ongoing anticoagulation within the last 6 months prior to study treatment; Myocardial infarction within the last 6 months prior to study treatment; Known HIV infection or active hepatitis B or C infection; Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, congestive heart failure New York Heart Association (NYHA) Class III or IV related to primary cardiac disease, uncontrolled ischemic or severe vascular heart disease; Known bleeding disorder (e.g., hemophilia, von Willebrand disease); Conditions that may predispose to major bleeding (e.g., active GI ulcers, upper or lower GI bleedings in the last 6 months, significant hemoptysis in the last 6 months, tumor invasion of major vessels, etc.). Conditions that have been treated may be allowed if resolution of the risk is documented; A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome); Use or indication for full dose anticoagulation or anti-platelet therapy including low dose aspirin; Women who are pregnant or lactating.